Ryvu Therapeutics S.A. (RVU.WA)
PLN 32.85
(1.39%)
PLN 32.85
(1.39%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -81.04 Million PLN | -61.46% |
| 2022 | -65.2 Million PLN | -2.69% |
| 2021 | -65.95 Million PLN | -262.36% |
| 2020 | -17.87 Million PLN | 33.24% |
| 2019 | -35.72 Million PLN | -582.3% |
| 2018 | -17.25 Million PLN | -125.9% |
| 2017 | 17.88 Million PLN | 520.54% |
| 2016 | 2.47 Million PLN | -156.64% |
| 2015 | 5.55 Million PLN | -19.06% |
| 2014 | 7.6 Million PLN | -96.19% |
| 2013 | -211.6 Thousand PLN | 4464.38% |
| 2012 | 159.28 Million PLN | -69.2% |
| 2011 | -3.02 Million PLN | -66.15% |
| 2010 | -1.67 Million PLN | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -23.55 Million PLN | 35.03% |
| 2024 Q2 | -27.55 Million PLN | -68.86% |
| 2023 Q2 | -25.68 Million PLN | -79.68% |
| 2023 Q1 | -14.29 Million PLN | -1079.11% |
| 2023 FY | - PLN | -61.46% |
| 2023 Q4 | -28.02 Million PLN | -69.59% |
| 2023 Q3 | -16.52 Million PLN | 35.67% |
| 2022 Q3 | -9.71 Million PLN | 64.41% |
| 2022 Q1 | -23.17 Million PLN | -69.6% |
| 2022 Q2 | -27.3 Million PLN | -17.84% |
| 2022 FY | - PLN | -2.69% |
| 2022 Q4 | 1.46 Million PLN | 115.02% |
| 2021 Q4 | -13.66 Million PLN | 29.5% |
| 2021 Q1 | -10.29 Million PLN | -65.57% |
| 2021 FY | - PLN | -262.36% |
| 2021 Q2 | -21.3 Million PLN | -107.03% |
| 2021 Q3 | -19.38 Million PLN | 9.04% |
| 2020 Q4 | -6.21 Million PLN | 28.93% |
| 2020 FY | - PLN | 33.24% |
| 2020 Q1 | -1.69 Million PLN | 27.73% |
| 2020 Q2 | -877.89 Thousand PLN | 48.33% |
| 2020 Q3 | -8.74 Million PLN | -896.22% |
| 2019 Q1 | -2.65 Million PLN | 58.94% |
| 2019 Q4 | -2.35 Million PLN | 75.05% |
| 2019 FY | - PLN | -582.3% |
| 2019 Q3 | -9.42 Million PLN | -145.1% |
| 2019 Q2 | -3.84 Million PLN | -45.01% |
| 2018 Q3 | 142.42 Thousand PLN | -80.24% |
| 2018 Q4 | -6.45 Million PLN | -4633.61% |
| 2018 FY | - PLN | -125.9% |
| 2018 Q2 | 720.88 Thousand PLN | -96.74% |
| 2018 Q1 | 22.14 Million PLN | 4965.53% |
| 2017 FY | - PLN | 520.54% |
| 2017 Q3 | 2.29 Million PLN | -50.28% |
| 2017 Q1 | 7.76 Million PLN | 677.53% |
| 2017 Q2 | 4.6 Million PLN | -40.66% |
| 2017 Q4 | 437.19 Thousand PLN | -80.91% |
| 2016 Q1 | -1.55 Million PLN | -13.56% |
| 2016 FY | - PLN | -156.64% |
| 2016 Q4 | 998.35 Thousand PLN | -66.96% |
| 2016 Q3 | 3.02 Million PLN | 67068.93% |
| 2016 Q2 | -4512.00 PLN | 99.71% |
| 2015 Q4 | -1.37 Million PLN | -152.14% |
| 2015 Q3 | 2.62 Million PLN | -7.27% |
| 2015 Q2 | 2.83 Million PLN | 29.27% |
| 2015 Q1 | 2.19 Million PLN | 3.56% |
| 2015 FY | - PLN | -19.06% |
| 2014 Q1 | 1.14 Million PLN | 16.15% |
| 2014 Q4 | 2.11 Million PLN | -8.29% |
| 2014 Q3 | 2.3 Million PLN | 1.99% |
| 2014 Q2 | 2.26 Million PLN | 97.49% |
| 2014 FY | - PLN | -96.19% |
| 2013 Q4 | 986.87 Thousand PLN | 476.34% |
| 2013 FY | - PLN | 4464.38% |
| 2013 Q1 | -971.56 Thousand PLN | 38.32% |
| 2013 Q2 | -906.07 Thousand PLN | 6.74% |
| 2013 Q3 | -262.22 Thousand PLN | 71.06% |
| 2012 Q3 | -479.9 Thousand PLN | 74.94% |
| 2012 FY | - PLN | -69.2% |
| 2012 Q2 | -1.91 Million PLN | -21.34% |
| 2012 Q1 | -1.57 Million PLN | 0.0% |
| 2012 Q4 | -1.57 Million PLN | -228.22% |
| 2011 FY | - PLN | -66.15% |
| 2010 FY | - PLN | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bioceltix S.A. | -13.22 Million PLN | -512.839% |
| BIOTON S.A. | 43.89 Million PLN | 284.623% |
| Captor Therapeutics Spolka Akcyjna | -64.76 Million PLN | -25.137% |
| Mabion S.A. | 58.31 Million PLN | 238.981% |
| Molecure S.A. | -25.5 Million PLN | -217.747% |
| NanoGroup S.A. | -7.87 Million PLN | -929.75% |
| Pharmena S.A. | 33.78 Million PLN | 339.917% |
| Poltreg S.A. | -11.65 Million PLN | -595.12% |
| Pure Biologics Spólka Akcyjna | -26.07 Million PLN | -210.787% |
| Synthaverse S.A. | 15.34 Million PLN | 628.112% |
| Urteste S.A. | -5.73 Million PLN | -1314.134% |